 |
10 Diseases |  |
0 Trials |
|
0 Trials |  |
39 News |  |
- || Gimoti (metoclopramide intranasal) / Evoke Pharma
Review, Journal: Current and emerging pharmacotherapy for the treatment of gastroparesis. (Pubmed Central) - Apr 17, 2024
The expansion of the research involving dopamine receptor antagonists and delving into alternative mechanisms of alleviating gastroparesis symptoms have been crucial in the landscape of gastroparesis. This is especially true as our knowledge of gastroparesis has proved that simply improving gastric emptying does not necessarily translate to clinical improvement.
- Gimoti (metoclopramide intranasal) / Evoke Pharma
TRANSFORMING DIABETIC GASTROPARESIS CARE IN WOMEN: INSIGHTS FROM NASAL METOCLOPRAMIDE USAGE (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5201;
The likelihood of a female DGP patient treated with NMCP being admitted to the hospital was less than a third of women treated with OMCP during the same period, and that of a visit to the ED or outpatient was less than half. The efficacy of NMCP in reducing hospital admissions and outpatient visits in women highlights its potential as a preferential treatment option in this demographic.
- ||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Clinical, P3 data, Journal: Metoclopramide Nasal Spray in Women with Symptomatic Diabetic Gastroparesis: A Randomized, Double-blind, Placebo-controlled Phase 3 Study. (Pubmed Central) - Nov 5, 2023
P3
Although the primary endpoint was not met using all enrolled patients, treatment with MNS provided significant relief for women with moderate to severe diabetic gastroparesis symptoms. MNS was well tolerated and demonstrated a similar safety profile to placebo.
- Gimoti (metoclopramide intranasal) / Evoke Pharma
Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients (West Ballroom B) - Jul 29, 2023 - Abstract #ACG2023ACG_348;
NMCP-treated patients incurred lower cost across care sites: IH = -$10,021 (95%CI: -17,666, -2,376; p-value=.01), ED = -$926 (-1,371, -481; p-value< .001), HO= -$3,247 (-5,428, -1,066; p-value=.004), and LHT = -$472 (-846, -98; p-value =.014). Total medical cost (sum of all sites) was $16,808 (8,196, 25,420; p-value< .001) lower in the NMCP cohort.
- Gimoti (metoclopramide intranasal) / Evoke Pharma
Real-world healthcare resource utilization of patients treated with metoclopramide nasalspray for diabetic gastroparesis () - Mar 26, 2023 - Abstract #AMCP2023AMCP_51;
Patients using nasal mcp demonstrated a decline in all-cause and DGP HRU pre- versus post-treatment for office, ED, inpatient and outpatient visits across all settings for the 6-month intervals following initiation of treatment with significant reductions in DGP-related PO, and HO and a numerical improvement for ED. Similar results are observed in all-cause HRU.
- Gimoti (metoclopramide intranasal) / Evoke Pharma
REDUCING REAL-WORLD HEALTHCARE RESOURCE UTILIZATION FOR PATIENTS WITH DIABETIC GASTROPARESIS (DGP) TREATED WITH METOCLOPRAMIDE NASAL SPRAY VERSUS ORAL METOCLOPRAMIDE (W190b - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_5652;
Similarly, DGP symptom-related HRU was significantly lower for NMCP patients across all settings (except for HO) including IH. Keywords: gastroparesis, metoclopramide, nasal, oral, healthcare resource utilization
- Gimoti (metoclopramide intranasal) / Evoke Pharma
USE OF MACHINE LEARNING TO IDENTIFY GASTROPARESIS PATIENT APPROPRIATE FOR NASAL SPRAY METOCLOPRAMIDE (South Hall A, Poster Hall - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_2630;
Diabetes is present in 51.5%. ML allows us to efficiently identify patients with similar profiles and clinical journey, who could benefit from initiation of NMCP.
- Gimoti (metoclopramide intranasal) / Evoke Pharma
Use of Real-World Data for Hard-to-Identify Patient Population: Methodology and a Case Study () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_652;
Identif ication of patients outside the routine healthcare sources is important to understand patient journeys , HCRU and experiences with healthcare settings , and decisions concerning new treatment s; this particularly becomes more imperative for hard-to-find patients such as DGP treated with nasal MCP . The c omprehensive , population-level information on health, medical, and HCRU derived from RWD can help inform healthcare decision - making .
- ||| Gimoti (metoclopramide intranasal) / Evoke Pharma
ANDA: $EVOK Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti https://t.co/kDCeZD2F3I (Twitter) - Jan 30, 2023
- | Gimoti (metoclopramide intranasal) / Evoke Pharma
$EVOK GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award https://t.co/K42NL6US0u (Twitter) - Sep 14, 2022
- ||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Reimbursement, Medicaid: $EVOK Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program https://t.co/vIm0wGG3CX (Twitter) - Jun 15, 2022
- Gimoti (metoclopramide intranasal) / Evoke Pharma
20236 - Emerging Strategies in Diabetic Gastroparesis Care: Rethinking the Status Quo (Harbor GH - Manchester Grand Hyatt Hotel) - May 16, 2022 - Abstract #DDW2022DDW_6942;
Explore the burden of DGP, unmet treatment need and the role of GIMOTI nasal spray in the treatment paradigm. Discuss potential benefits of the nasal route of administration and the challenge of treating DGP patients with oral meds. Supported by Evoke Pharma
- || Gimoti (metoclopramide intranasal) / Evoke Pharma
$EVOK Evoke Pharma Granted FDA Market Exclusivity for GIMOTI® https://t.co/6eu3X6LAUM (Twitter) - Apr 26, 2022
- ||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Reimbursement, Medicaid: $EVOK Evoke Pharma Announces Approval of GIMOTI® to the Texas Medicaid Preferred Drug List https://t.co/uUeswcszPk (Twitter) - Apr 19, 2022
- ||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Licensing / partnership: $EVOK Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI https://t.co/B4UAyCFE27 (Twitter) - Feb 2, 2022
- || Gimoti (metoclopramide intranasal) / Evoke Pharma
Clinical, Journal: Metoclopramide nasal spray for management of symptoms of acute and recurrent diabetic gastroparesis in adults. (Pubmed Central) - Jan 29, 2022
Now, more than 40 years later, a nasal preparation of metoclopramide (Gimoti) was approved in June 2020 for the same indication.Areas covered: PubMed search using the keywords 'nasal metoclopramide' and 'diabetic gastroparesis.' This article aims to provide a concise review of the pharmacology, clinical efficacy, and tolerability of nasal metoclopramide.Expert opinion: The nasal formulation can be systemically absorbed without relying on the passage through a poorly emptying stomach, thus assuring the delivery of a therapeutic dose of metoclopramide, even during episodes of vomiting. Hence, metoclopramide nasal spray has the potential to be used during an acute flare, potentially avoiding hospitalizations.
- || Zeposia (ozanimod) / BMS, Gimoti (metoclopramide intranasal) / Evoke Pharma, budesonide / Generic mfg.
In the meantime, check out all our breakthrough nominees: Zeposia (Ozanimod, @ScienceAtBMS), Gimoti (metoclopramide, Evoke Pharma), SuTab (sulfate prep, Sebela Pharmaceuticals), @Cologuard and Budesonide (@TakedaPharma) (Twitter) - Oct 23, 2021
- ||| Gimoti (metoclopramide intranasal) / Evoke Pharma
New metoclopramide nasal spray (Gimoti) can worsen Parkinson's: Tips on treating GI issues if you have Parkinson's. Check out our new blog post: https://t.co/YbM70sDq3v @PdAvengers @ParkinsonDotOrg @basbloem @DrISubramanian @pdinfocus @endingpdbook (Twitter) - Jul 27, 2021
- | Gimoti (metoclopramide intranasal) / Evoke Pharma
Journal: Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis. (Pubmed Central) - Jul 21, 2021
Hence, metoclopramide nasal spray has the potential to be used during an acute flare, potentially avoiding hospitalizations. No abstract available
- || Gimoti (metoclopramide intranasal) / Evoke Pharma
$EVOK Evoke Pharma and EVERSANA Launch Social Media Campaign for Gimoti® Nasal Spray https://t.co/I8KrboVj8V (Twitter) - May 27, 2021
- | Gimoti (metoclopramide intranasal) / Evoke Pharma
Journal: Metoclopramide nasal spray (Gimoti) for diabetic gastroparesis. (Pubmed Central) - Mar 10, 2021
No abstract available No abstract available
- ||||||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Trial completion, Trial primary completion date: Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis (clinicaltrials.gov) - Feb 9, 2017
P3, N=53, Completed, Sponsor: Evoke Pharma
No abstract available Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Aug 2016
- ||||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Enrollment closed, Enrollment change: Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis (clinicaltrials.gov) - Oct 19, 2016
P3, N=53, Active, not recruiting, Sponsor: Evoke Pharma
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Aug 2016 Recruiting --> Active, not recruiting | N=150 --> 53
- |||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Trial primary completion date: Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis (clinicaltrials.gov) - Aug 11, 2016
P3, N=150, Recruiting, Sponsor: Evoke Pharma
Recruiting --> Active, not recruiting | N=150 --> 53 Trial primary completion date: Jul 2016 --> Dec 2016
- ||||||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Trial completion: Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis (clinicaltrials.gov) - Aug 11, 2016
P3, N=205, Completed, Sponsor: Evoke Pharma
Trial primary completion date: Jul 2016 --> Dec 2016 Recruiting --> Completed
- |||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Trial primary completion date: Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis (clinicaltrials.gov) - Dec 29, 2015
P3, N=150, Recruiting, Sponsor: Evoke Pharma
Recruiting --> Completed Trial primary completion date: Nov 2015 --> Jul 2016
- |||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Trial primary completion date: Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis (clinicaltrials.gov) - Dec 29, 2015
P3, N=200, Recruiting, Sponsor: Evoke Pharma
Trial primary completion date: Nov 2015 --> Jul 2016 Trial primary completion date: Nov 2015 --> Jul 2016
- |||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Trial primary completion date: Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis (clinicaltrials.gov) - Jun 30, 2015
P3, N=150, Recruiting, Sponsor: Evoke Pharma
Trial primary completion date: Nov 2015 --> Jul 2016 Trial primary completion date: Jul 2015 --> Nov 2015
- |||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Trial primary completion date: Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis (clinicaltrials.gov) - Jun 30, 2015
P3, N=200, Recruiting, Sponsor: Evoke Pharma
Trial primary completion date: Jul 2015 --> Nov 2015 Trial primary completion date: Jul 2015 --> Nov 2015
- ||||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Trial initiation date: Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis (clinicaltrials.gov) - Apr 20, 2014
P3, N=150, Recruiting, Sponsor: Evoke Pharma
Trial primary completion date: Jul 2015 --> Nov 2015 Initiation date: Jun 2014 --> Apr 2014
- ||||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Trial initiation date: Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis (clinicaltrials.gov) - Apr 20, 2014
P3, N=200, Recruiting, Sponsor: Evoke Pharma
Initiation date: Jun 2014 --> Apr 2014 Initiation date: Jun 2014 --> Apr 2014
- |||||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Enrollment open: Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis (clinicaltrials.gov) - Apr 20, 2014
P3, N=150, Recruiting, Sponsor: Evoke Pharma
Initiation date: Jun 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- |||||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Enrollment open: Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis (clinicaltrials.gov) - Apr 20, 2014
P3, N=200, Recruiting, Sponsor: Evoke Pharma
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Gimoti (metoclopramide intranasal) / Evoke Pharma
New P3 trial: Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis (clinicaltrials.gov) - Dec 30, 2013
P3, N=150, Recruiting, Sponsor: Evoke Pharma
- |||||||||| Gimoti (metoclopramide intranasal) / Evoke Pharma
New P3 trial: Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis (clinicaltrials.gov) - Dec 30, 2013
P3, N=200, Recruiting, Sponsor: Evoke Pharma
- ||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Enrollment change: Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis (clinicaltrials.gov) - May 27, 2013
P2, N=287, Completed, Sponsor: Evoke Pharma
Not yet recruiting --> Recruiting N=225 --> 287
- |||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Trial completion: Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis (clinicaltrials.gov) - May 27, 2013
P2, N=287, Completed, Sponsor: Evoke Pharma
N=225 --> 287 Active, not recruiting --> Completed